23982-92-5

Basic information

• Product Name: 1-benzyl-6-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole
• Synonyms: 1-benzyl-6-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole
• CAS NO: 23982-92-5
• Molecular Weight: 285.348
• Mol File: 23982-92-5.mol

Chemical Properties

• CAS DataBase Reference: 1-benzyl-6-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-6-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole(23982-92-5)
• EPA Substance Registry System: 1-benzyl-6-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole(23982-92-5)

Safety Data

• Hazardous Substances Data: 23982-92-5(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 5729-06-6 N-benzyl-2-nitroaniline 
• 872-85-5 pyridine-4-carbaldehyde 
• 5822-13-9 N-benzyl-1,2-phenylenediamine 
• 39178-35-3 isonicotinoyl chloride hydrochloride 
• 95-51-2 o-chloroaniline 
• 1397687-20-5 (Z)-N-(2-chlorophenyl)isonicotinimidoyl chloride 
• 51991-73-2 N-(2-chlorophenyl)-4-pyridinecarboxamide 

Relevant articles and documents

Benzimidazole Derivatives as Novel Zika Virus Inhibitors

We have synthesized 50 benzimidazole (BMZ) derivatives with 1,2-phenylenediamines and aromatic aldehydes under mild oxidation conditions by using inexpensive, nontoxic inorganic salt sodium metabisulfite in a one-pot condensation reaction and screened their ability to interfere with Zika virus (ZIKV) infection utilizing a cell-based phenotypic assay. Seven BMZs inhibited an African ZIKV strain with a selectivity index (SI=CC50/EC50) of 9–37. Structure-activity relationship analysis demonstrated that substitution at the C-2, N-1, and C-5 positions of the BMZ ring were important for anti-ZIKV activity. The hybrid structure of BMZ and naphthalene rings was a structural feature responsible for the high anti-ZIKV activity. Importantly, BMZs inhibited ZIKV in human neural stem cells, a physiologically relevant system considering the severe congenital anomalies, like microcephaly, caused by ZIKV infection. Compound 39 displayed the highest antiviral efficacy against the African ZIKV strain in Huh-7 (SI>37) and neural stem cells (SI=12). Compound 35 possessed the highest activity in Vero cells (SI=115). Together, our data indicate that BMZs derivatives have to be considered for the development of ZIKV therapeutic interventions.

Benzimidazole compound with endothelial lipase inhibition effect and application of benzimidazole compound

The invention discloses a benzimidazole compound with an endothelial lipase inhibition effect and application of the benzimidazole compound, and belongs to the technical field of medicines. The benzimidazole compound has an excellent inhibition effect on endothelial lipase, can effectively treating atherosclerosis and sequelae thereof, such as coronary heart disease, and also promotes treatment onmetabolic syndrome and sequelae thereof, such as diabetes. The benzimidazole compound provided by the invention has good solubility in an aqueous medium, also has good biological activity and metabolic stability, and shows advantages in the aspect of serum stability.

Palladium-catalyzed synthesis of benzimidazoles and quinazolinones from common precursors

N-(o-Halophenyl)imidoyl chlorides and the corresponding imidates are easily prepared and can be utilized as complementary precursors for the synthesis of important heterocycles. The synthesis of N-substituted benzimidazoles was possible from the palladium